- Home
- BHC vs ADRX Comparison
BHC vs ADRX Comparison
Compare BHC & ADRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHC | ADRX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1996 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BHC | ADRX |
|---|---|---|
| Price | $8.26 | $16.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $7.70 | ★ $34.25 |
| AVG Volume (30 Days) | ★ 3.0M | 429.1K |
| Earning Date | 10-28-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 423.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,724,000,000.00 | N/A |
| Revenue This Year | $6.81 | $72.35 |
| Revenue Next Year | N/A | $570.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.33 | $16.61 |
| 52 Week High | $9.04 | $19.57 |
Technical Indicators
Market Signals| Indicator | BHC | ADRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.93 | 35.12 |
| Support Level | $5.49 | N/A |
| Resistance Level | N/A | $19.01 |
| Average True Range (ATR) | 0.37 | 1.20 |
| MACD | 0.24 | -0.03 |
| Stochastic Oscillator | 78.69 | 11.74 |
Price Performance
Historical ComparisonAbout BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
About ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.